polivy-logo-triangle.svg

Efficacy

POLIVY-R-CHP was superior to R-CHOP, with significantly reduced risk of disease progression, relapse, or death1,*

Watch Expert Perspectives

Specialist views covering a range of POLARIX trial topics

watch-expert-perspectives-image1.png

Dr Hervé Tilly,
University of Rouen, France

watch-expert-perspectives-image2.png

Prof. Christopher Flowers,
MD, Anderson Cancer Center, University of Texas

watch-expert-perspectives-image3.png

Dr Franck Morschhauser,
MD, PhD Professor of Hematology,
University of Lille

watch-expert-perspectives-image4.png

Dr Laurie H. Sehn,
MD, MPH Clinical Assistant
Professor with the BC Cancer Agency and University
of British Columbia

POLIVY-R-CHP brings clinically meaningful improvement over R-CHOP1

efficacy-27-percent-min.png

POLIVY-R-CHP was superior vs the current SoC: there was a 27% reduction of the risk of progression, relapse or death compared
to R-CHOP1

Stratified hazard ratio 0.73; 95% CI, 0.57–0.95; p=0.021

efficacy-6-percent-min.png

At 24 months, there was a 6.5% improvement in progression-free survival with POLIVY-R-CHP vs R-CHOP1

 

76.7% (95% CI, 72.7– 80.8) vs. 70.2% (95% CI, 65.8-74.6)1

quote.svg

“Out of every four patients that would potentially relapse on R-CHOP you’re now preventing one of those four patients from relapsing with the POLIVY-R-CHP combination.”

– Dr Laurie H. Sehn, MD, MPH

Clinical Assistant Professor with the BC Cancer
Agency and University of British Columbia

Investigator-assessed progression-free survival (PFS)1,2

Results of POLARIX (Clinical cut-off date: June 15, 2022) show a continued benefit of POLIVY treatment through 3 years1,2

Primary endpoint: Investigator-assessed PFS

investigator-assessed-graph.png

Investigator-assessed event-free survival (EFS†) — a key secondary endpoint — confirmed the PFS results and hence the clinical benefit demonstrated by POLIVY-R-CHP (HR = 0.75 [95% CI: 0.58, 0.96], p-value = 0.02).1 EFS showed a 25% reduction in the risk of death, progression, relapse, or other events.1,‡

Primary endpoint:

Investigator-assessed PFS

investigator-assessed-graph-mobile.png

Investigator-assessed event-free survival (EFS†) — a key secondary endpoint — confirmed the PFS results and hence the clinical benefit demonstrated by POLIVY-R-CHP (HR = 0.75 [95% CI: 0.58, 0.96], p-value = 0.02).1 EFS showed a 25% reduction in the risk of death, progression, relapse, or other events.1,‡

Similar efficacy was seen across patient subgroups3,4

Elderly patients ( ≥70 years)3

  • In patients aged >70–80 years, efficacy endpoints favoured POLIVY-R-CHP vs. R-CHOP, including progression-free survival as observed in the ITT population3
  • The analysis of this elderly population confirms the risk-benefit profile of POLIVY-R-CHP that was observed in the ITT population3

High-risk patients (young patients age ≤60 years, high‐risk aaIPI 2,3)4,§

  • No significant differences in efficacy were seen in high-risk patients receiving POLIVY-R-CHP or R-CHOEP4
  • Similar efficacy was seen across patient subgroups regardless of aaIPI 2 or 3 status4

§A retrospective analysis based on results from the POLIVY-R-CHP arm of POLARIX and the R-CHOEP arm of the Phase III Mega-CHOEP study4

POLIVY-R-CHP has the potential to decrease the burden of R/R disease1

Patients Receiving Subsequent Lymphoma Therapy (ITT Population)

Graph_02_Patients Receiving Subsequent Lymphoma Therapy.png

POLIVY-R-CHP has the potential to decrease the burden of R/R disease1

  • Fewer patients with POLIVY-R-CHP had subsequent lines of therapies (17.0% with POLIVY-R-CHP compared to 23.5% with R-CHOP)1
  • Amongst those patients, fewer needed intensive high-cost and high-risk therapies such as CAR-T and SCT (47 patients in the R-CHOP arm vs 26 patients in the POLIVY-R-CHP arm)1
quote.svg

“What we want to do is try and cure them with front-line therapy, and we know that the stakes become a lot higher once they do relapse.”

– Dr Laurie H. Sehn, MD, MPH

Clinical Assistant Professor with the BC Cancer
Agency and University of British Columbia

In 1L DLBCL, PFS strongly predicts the treatment effects on overall survival5

quote.svg

“We clearly established that progression-free survival is a surrogate for overall survival.”

– Prof. Christopher Flowers

University of Texas MD Anderson Cancer Center

Safety

How does the safety data for POLIVY-R-CHP compare to that of R-CHOP?

people-efficacy-min.png

*Stratified hazard ratio 0.73; 95% CI, 0.57–0.95; p=0.021

†EFS defined as the time from randomisation to the earliest occurrence of disease progression/relapse, death due to any cause, initiation of any non-protocol specified anti-lymphoma treatment, or biopsy-confirmed residual disease after treatment completion.

‡Events of progression or relapse were assessed by the investigator. Other events are subsequent therapy for lymphoma or biopsy-confirmed residual disease after treatment.

§A retrospective analysis based on results from the POLIVY-R-CHP arm of POLARIX and the R-CHOEP arm of the Phase III Mega-CHOEP study4

 

1L=first line; aaIPI=age-adjusted International Prognostic Index; CAR-T=chimeric antigen receptor T-cell therapy; DLBCL=diffuse large B-cell lymphoma; NE=not able to be evaluated; PFS=progression-free survival; POLIVY-R-CHP=polatuzumab vedotin + rituximab, cyclophosphamide, doxorubicin, prednisone; R/R=relapsed or refractory; R-CHOP=rituximab + cyclophosphamide, doxorubicin, vincristine, prednisone; SCT=stem-cell therapy; SoC=standard of care.

 

References:

  1. Tilly H, et al. N Engl J Med. 2022;386:351-63.
  2. Herrera A, et al. Poster presented at: 2022 ASH; December 2022; New Orleans, LA.
  3. Hu B, et al. Poster presented at: 17th ICML; June 2023; Lugano, Switzerland.
  4. Lenz G, et al. Poster presented at: 17th ICML; June 2023; Lugano, Switzerland. 2023.
  5. Shi Q, et al. J Clin Oncol. 2018;36:2593-602.